GEHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GE Healthcare Technologies Inc. is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock is close to pivot support and has mixed technicals, but the lack of an Intellectia proprietary buy signal, a recent guidance cut, and broad analyst target reductions make the setup more of a wait-and-see than an immediate purchase. If the investor is impatient and wants to buy now, this is still only a hold, not a clear buy.
Pre-market price is 62.89, almost flat (+0.05%), with the stock sitting just above pivot 63.109 and near S1 at 61.214. MACD histogram is positive at 0.568 but contracting, which suggests momentum is still positive but weakening. RSI_6 at 43.916 is neutral-to-soft, and moving averages are converging, showing no strong trend. Short-term candlestick pattern data suggests limited near-term upside and possible weakness over the next week. Overall, the chart is range-bound and lacks a convincing breakout signal.
Latest quarter: Q1. GE HealthCare reported adjusted EPS of $0.99 and lowered its full-year guidance to $4.80-$5.00 from $4.95-$5.15, versus consensus around $5.06. That points to weaker-than-expected near-term earnings momentum. Since detailed revenue figures were not provided, the main financial takeaway is that growth expectations have been reset lower and margin pressure has increased, even though management and some analysts still see longer-term business strength.
Recent analyst activity shows a clear downward revision trend in price targets after the Q1 miss and guidance cut. Evercore ISI lowered target to $80 and kept Outperform; Oppenheimer lowered to $85 and kept Outperform; Stifel lowered to $80 and kept Buy; Piper Sandler lowered to $88 and kept Overweight; Mizuho lowered to $90 and kept Outperform. On the bearish side, JPMorgan and Citi both cut targets to $65 and stayed Neutral, Barclays cut to $78 and stayed Equal Weight, Goldman Sachs downgraded to Neutral with a $65 target, and UBS upgraded from Sell to Neutral while cutting to $69. Wall Street is split, but the pros still see long-term product and ecosystem strengths, while the cons focus on earnings misses, lower guidance, inflation, tariffs, and China exposure. Overall, the Street tone has become more cautious.
